The Management of Patients With Hepatorenal Syndrome-Acute Kidney Injury: An International Perspective

Target Audience
This activity was developed for a national audience of critical care physicians, hepatologists, nephrologists, transplant surgeons, critical care pharmacists, nurse practitioners, physician assistants, and other clinicians who care for patients with hepatorenal syndrome-acute kidney injury (HRS-AKI).

Program Overview
During these paired conversations, the faculty explore revised diagnostic criteria, emerging treatment, and coordinating effective multidisciplinary care. In addition, the faculty panel collaboratively reviews a patient case for which they share their international perspectives on the nonpharmacological and pharmacological treatment of patients with HRS-AKI.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Implement American Association for the Study of Liver Disease (AASLD) criteria in the diagnosis of patients with HRS-AKI
Discuss the role of nonpharmacologic and pharmacologic therapies for the treatment of HRS-AKI according to current AASLD and Society of Critical Care Medicine (SCCM) guideline recommendations
Compare the clinical pharmacology of currently available and emerging vasoconstrictors for HRS-AKI
Describe the safety and efficacy of vasoconstrictor options for the treatment of patients with HRS-AKI, based on clinical trials and real-world, international experience
Compare treatment approaches to HRS-AKI recommended in AASLD and SCCM guidelines
Apply current guideline recommendations as a multidisciplinary care team in treating patients with HRS-AKI